CN1051706C - 氨基氢化喹唑啉类化合物及其衍生物戒降药物依赖性的新用途 - Google Patents
氨基氢化喹唑啉类化合物及其衍生物戒降药物依赖性的新用途 Download PDFInfo
- Publication number
- CN1051706C CN1051706C CN95190556A CN95190556A CN1051706C CN 1051706 C CN1051706 C CN 1051706C CN 95190556 A CN95190556 A CN 95190556A CN 95190556 A CN95190556 A CN 95190556A CN 1051706 C CN1051706 C CN 1051706C
- Authority
- CN
- China
- Prior art keywords
- derivant
- oxazoline compound
- application
- nap
- hydrogenated quinazoline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
用药天数 | A组 | B组 | C组 | D组 | ||
TTX,im,μg | TTX,im,μg | C1 | C2 | D1 | D2 | |
n=1000 | n=1000 | TTX.im/iv,μg | TTX.im/iv,μg | 美沙PO(mg) | DHEμg | |
d1 | 30 | 60 | 60+美沙酮30mg po | 60+安定10mg+氯氮平25mg | 30 | 400iv |
d2 | 30 | 60+安定10-20mg 500ml葡萄糖水 | 60+美沙酮30mg po | 60+安定10mg+氯氮平25mg | 30 | 400iv |
d3 | 30 | 同上 | 60+美沙酮20mg po | 同上 | 30 | 400iv |
d4 | 60 | 同上 | 同上 | 20 | 350po | |
d5 | 30 | 30+美沙酮10mg po | 同上 | 15 | 300po | |
d6 | 30 | 同上 | 30+安定10mg | 15 | 200po | |
d7 | 30 | 同上 | 10 | 150po | ||
d8 | 5 | 100po |
分组 | 病例数 | 72h效果 | 末期效果 | 有效率% | ||||
显效 | 有效 | 无效 | 显效 | 有效 | 无效 | |||
治疗组A | 1000 | 970 | 30 | 0 | 950 | 50 | 0 | 100 |
治疗组B | 1000 | 750 | 240 | 10 | 510 | 488 | 2 | 98.8 |
治疗组C1 | 250 | 100 | 125 | 25 | 75 | 170 | 5 | 98 |
治疗组C2 | 250 | 80 | 120 | 50 | 60 | 183 | 7 | 97.2 |
治疗组D1 | 20 | 10 | 8 | 2 | 5 | 14 | 1 | 95 |
治疗组D2 | 20 | 12 | 6 | 2 | 6 | 13 | 1 | 95 |
日期 | A组 | B组 | C组 | D组 | ||
C1 | C2 | D1 | D2 | |||
治疗前 | 10.0±0 | 16.5±2.3 | 25.4±3.2 | 25.5±3.3 | 17.4±7.9 | 17.4±2.0 |
治疗d1 | 5.0±1.5 | 11.6±1.4 | 16.8±4.2 | 12.7±2.9 | 11.0±3.0 | 5.1±3.2 |
治疗d2 | 3.5±1.5 | 8.3±1.9 | 9.6±2.5 | 9.9±2.5 | 10.0±2.9 | 4.5±3.3 |
治疗d3 | 1.9±1.3 | 6.0±2.0 | 9.5±2.3 | 8.0±2.7 | 8.1±2.6 | 3.3±2.5 |
治疗d4 | 4.4±1.8 | 7.1±1.3 | 6.2±2.1 | 7.3±2.3 | 6.5±3.7 | |
治疗d5 | 1.6±1.5 | 5.1±1.7 | 5.2±1.8 | 5.5±2.1 | 5.5±2.9 | |
治疗d6 | 4.3±1.4 | 4.3±1.7 | 4.4±1.5 | 4.3±1.2 | ||
治疗d7 | 1.6±1.4 | 1.6±1.5 | 2.1±1.6 | 3.1±1.5 | ||
治疗d8 | 1.3±1.5 | 1.3±1.4 | 4.5±1.0 | 2.8±1.7 |
戒断症状 | A组治疗 | B组治疗 | C1组治疗 | C2组治疗 | D1组治疗 | D2组治疗 |
前(15min)72h后 | 前(15min)72h后 | 前(15min)72h后 | 前(15min)72h后 | 前(15min)72h后 | 前(15min)72h后 | |
流泪 | 983(81)1 | 985(180)120 | 246(210)171 | 245(208)71 | 19(20)17 | 18(3)19 |
流涕 | 980(40)31 | 1000(112)101 | 250(167)198 | 250(200)77 | 20(20)18 | 19(3)20 |
呵欠 | 921(450)21 | 999(720)57 | 250(172)98 | 250(198)42 | 20(20)16 | 20(10)20 |
失眠 | 998(350)98 | 998(620)512 | 250(160)198 | 25(220)72 | 19(19)17 | 19(18)18 |
鸡皮疙瘩 | 921(80)2 | 958(120)81 | 245(42)25 | 246(41)41 | 17(19)18 | 18(18)18 |
呕吐 | 142(0)0 | 167(34)11 | 47(40)3 | 50(41)0 | 7(8)8 | 4(1)8 |
恶心 | 640(0)0 | 941(100)20 | 236(41)7 | 225(40)3 | 15(17)15 | 14(7)11 |
厌食 | 945(400)41 | 958(801)122 | 241(202)51 | 240(240)230 | 18(19)20 | 19(17)19 |
焦躁不安 | 998(151)123 | 998(670)210 | 250(240)50 | 250(210)17 | 19(20)19 | 18(17)20 |
周身疼痛 | 888(101)140 | 966(121)720 | 248(240)247 | 241(240)247 | 17(19)18 | 17(13)18 |
腹痛腹泻 | 850(32)21 | 900(401)120 | 247(128)33 | 235(131)17 | 15(16)14 | 16(16)17 |
肌肉震颤 | 683(121)90 | 590(252)257 | 130(60)57 | 150(48)12 | 11(11)13 | 10(13)17 |
脉搏加快 | 830(71)3 | 835(307)123 | 213(200)35 | 215(147)35 | 10(14)18 | 10(14)19 |
忽冷忽热 | 958(21)0 | 960(25)3 | 249(120)7 | 245(98)8 | 18(20)19 | 17(14)18 |
瞳孔(mm) | 2.8±0.31.4±0.8 | 2.9±0.81.8±0.5 | 2.3±0.51.3±0.7 | 2.8±0.51.9±1.0 | 2.5±0.41.9±1.1 | 2.4±0.71.7±0.7 |
软弱无力 | 767(667)672 | 880(701)808 | 245(245)246 | 225(224)248 | 15(17)19 | 18(7)19 |
渴求 | 999(450)720 | 1000(611)881 | 250(249)125 | 250(230)247 | 20(20)20 | 20(19)20 |
日期 | A组n=1000 | B组n=1000 | C1组n=250 | C2组n=250 | D1组n=20 | D2组n=20 |
X±S | X±S | X±S | X±S | X±S | X±S | |
治疗前 | 22±4 | 24±5 | 25±5 | 22±4 | 22±4 | 22±4 |
后d1 | 11±5 | 13±6 | 11±5 | 18±5 | 11±5 | 3.3±2.5 |
d2 | 8±4 | 11±5 | 8±5 | 11±5 | 8±5 | 3.2±2.5 |
d3 | 7±3 | 10±4 | 5.1±2.8 | 10±4 | 5±3 | 2.3±1.5 |
d4 | 4±3 | 8±4 | 4.8±2.8 | 7±3 | 4.8±3 | 8±5 |
d5 | 3±2 | 4±2 | 4±3 | 5±7 | 4±3 | 6±3 |
d6 | 3±2 | 4±3 | 4±3 | 0±3 | 0.7±2.7 | |
d7 | 6.4±2.2 | 3.5±2.5 | 5.3±2 | 4.9±2.6 | ||
d8 | 7.0±2.7 | 3±2.5 | 4±2.5 | 4.5±3.0 |
病例号 | 性别 | 中毒种类 | 年限 | 毒品使用量/日 | 毒品使用方法 | 脱瘾药 | 用量 | 使用方式 | 使用天数 |
1 | 男 | 海洛因 | 4 | 0.2g | 静脉注射 | (1) | 30μg×10 | im | 5 |
2 | 男 | 鸦片 | 4 | 0.4g | 吸入 | (2) | 150μg×8 | im | 3 |
3 | 男 | 鸦片 | 1 | 0.4g | 吸入 | (3) | 100μg×5 | im | 2 |
4 | 男 | 海洛因 | 7个月 | 1.0g | 吸入 | (4) | 100μg×4 | im | 3 |
5 | 男 | 海洛因 | 3 | 1.0g | 吸入 | (5) | 100μg×8 | im | 4 |
6 | 男 | 海洛因 | 1 | 1.0g | 吸入 | (6) | 150μg×5 | im | 3 |
7 | 女 | 海洛因 | 1.6 | 0.8g | 静脉注射 | (7) | 30μg×8 | iv | 6 |
8 | 男 | 鸦片 | 1 | 0.2g | 吸入 | (8) | 30μg×7 | im | 3 |
9 | 男 | 鸦片 | 4 | 0.8g | 吸入 | (9) | 60μg×6 | im | 4 |
10 | 男 | 海洛因 | 4 | 1.0g | 吸入 | (10) | 60μg×6 | im | 3 |
11 | 男 | 海洛因 | 5 | 0.4g | 吸入 | (11) | 60μg×10 | im | 3 |
12 | 男 | 海洛因 | 4 | 1.0g | 吸入 | (12) | 60μg×12 | im | 6 |
13 | 男 | 海洛因 | 5 | 1.2g | 静脉注射 | (8) | 30μg×11 | iv | 4 |
14 | 男 | 海洛因 | 9 | 0.5g | 吸入 | (11) | 60μg×4 | im | 4 |
15 | 男 | 海洛因 | 5 | 1.5g | 静脉注射 | (12) | 60μg×13 | iv | 4 |
16 | 男 | 海洛因 | 1 | 0.5g | 静脉注射 | (10) | 60μg×5 | im | 3 |
17 | 男 | 鸦片 | 5 | 1.5g | 吸入 | (2) | 150μg×5 | im | 5 |
18 | 男 | 鸦片 | 20 | 1.2g | 吸入 | (3) | 100μg×3 | im | 5 |
19 | 男 | 海洛因 | 2 | 2.5g | 吸入 | (1) | 30μg×7 | im | 7 |
20 | 男 | 海洛因 | 5 | 3.5g | 静脉注射 | (1) | 30μg×8 | iv | 6 |
病例 | 自觉症状 | 他觉症状 | |||||||||||||||||||||||||||||||||
烦躁感 | 关节四肢痛 | 冷感 | 失眠 | 兴奋 | 口渴 | 呼吸困难 | 头痛 | 腹痛 | 恶心 | 下肢酸痛 | 胸部苦闷 | 胃痛 | 哈欠 | 皮肤痒 | 流泪 | 手指震颤 | 流鼻涕 | 散瞳 | 缩瞳 | 呕吐 | 下痢 | 恶心 | 流涎 | 辗转反侧 | 脚足烦躁 | 腹鸣 | 咳嗽 | 失调 | 呻吟 | 发汗 | 尿蛋白 | 呼吸数 | 脉搏 | 血压 | |
1 | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | 20 | 88 | 90/60 | ||||||||||||
2 | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | 20 | 84 | 100/70 | ||||||||||
3 | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | 18 | 80 | 100/70 | |||||||||||||||
4 | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | 20 | 88 | 90/80 | ||||||||||||||||
5 | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | 20 | 82 | 90/60 | ||||||||||||||
6 | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | 20 | 90 | 90/60 | |||||||||||||||||
7 | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | 20 | 90 | 90/60 | ||||||||||||||||
8 | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | 20 | 84 | 100/70 | |||||||||||||||||
9 | + | + | + | + | + | + | + | + | + | + | + | + | 20 | 88 | 96/70 | ||||||||||||||||||||
10 | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | 20 | 84 | 90/60 | ||||||||||||||||
11 | + | + | + | + | + | + | + | + | + | + | + | + | + | + | 18 | 80 | 100/70 | ||||||||||||||||||
12 | + | + | + | + | + | + | + | + | + | + | + | + | + | 20 | 72 | 100/88 | |||||||||||||||||||
13 | + | + | + | + | + | + | + | + | + | + | + | 20 | 84G | 100/70 | |||||||||||||||||||||
14 | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | 20 | 82 | 90/60 | ||||||||||||||
15 | + | + | + | + | + | + | + | + | + | 20 | 76 | 96/68 | |||||||||||||||||||||||
16 | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | 20 | 90 | 100/70 | |||||||||||||||
17 | + | + | + | + | + | + | + | + | + | + | + | + | + | 20 | 90 | 90/60 | |||||||||||||||||||
18 | + | + | + | + | + | + | + | + | + | + | + | + | + | 20 | 84 | 90/60 | |||||||||||||||||||
19 | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | 20 | 84 | 90/80 | |||||||||||||||||
20 | + | + | + | + | + | + | + | + | + | + | + | + | + | + | 20 | 88 | 90/70 |
病例 | 本发明化合物注射(后)5min-15min | 第四天 | |||
舌口唇纯麻感 | 四肢纯麻感 | 患者自身感觉 | 脉搏(注射后血压无显著变化 | 尿液测吗啡结果 | |
1 | (+) | 良好 | 74 | 阴性(-) | |
2 | (+) | (+) | 良好 | 78 | 阴性(-) |
3 | (+) | (+) | 良好 | 78 | 阴性(-) |
4 | (+) | 不好 | 86 | 阴性(-) | |
5 | (+) | (+) | 良好 | 80 | 阴性(-) |
6 | (+) | 良好 | 86 | 阴性(-) | |
7 | (+) | 良好 | 86 | 阴性(-) | |
8 | (+) | 良好 | 80 | 阴性(-) | |
9 | (+) | 良好 | 82 | 阴性(-) | |
10 | (+) | (+) | 良好 | 80 | 阴性(-) |
11 | (+) | 良好 | 76 | 阴性(-) | |
12 | (+) | 良好 | 70 | 阳性(+) | |
13 | (+) | (+) | 良好 | 80 | 阴性(-) |
14 | (+) | 良好 | 78 | 阴性(-) | |
15 | (+) | 良好 | 74 | 阳性(+) | |
16 | (+) | (+) | 良好 | 86 | 阳性(+) |
17 | (+) | 良好 | 84 | 阴性(-) | |
18 | (+) | 良好 | 80 | 阴性(-) | |
19 | (±) | (±) | 良好 | 84 | 阴性(-) |
20 | (-) | 良好 | 84 | 阳性(+) |
Claims (16)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN95190556A CN1051706C (zh) | 1994-03-17 | 1995-03-11 | 氨基氢化喹唑啉类化合物及其衍生物戒降药物依赖性的新用途 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN94110873.2 | 1994-03-17 | ||
CN95190556A CN1051706C (zh) | 1994-03-17 | 1995-03-11 | 氨基氢化喹唑啉类化合物及其衍生物戒降药物依赖性的新用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1051706C true CN1051706C (zh) | 2000-04-26 |
Family
ID=33853859
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN95190556A Expired - Lifetime CN1051706C (zh) | 1994-03-17 | 1995-03-11 | 氨基氢化喹唑啉类化合物及其衍生物戒降药物依赖性的新用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1051706C (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100360133C (zh) * | 2002-05-23 | 2008-01-09 | 潘心富 | 用于戒毒、镇痛的河豚毒素呼吸道给药制剂 |
CN102020653A (zh) * | 2009-09-22 | 2011-04-20 | 江苏宏锦天药业有限公司 | 氨基全氢化喹唑啉类化合物及其衍生物制备提高抗癌药药效的新应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3898339A (en) * | 1973-08-14 | 1975-08-05 | Astra Pharma Prod | Spinal anesthesia using small amounts of tetrodotoxin or desoxytetrodotoxin |
-
1995
- 1995-03-11 CN CN95190556A patent/CN1051706C/zh not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3898339A (en) * | 1973-08-14 | 1975-08-05 | Astra Pharma Prod | Spinal anesthesia using small amounts of tetrodotoxin or desoxytetrodotoxin |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100360133C (zh) * | 2002-05-23 | 2008-01-09 | 潘心富 | 用于戒毒、镇痛的河豚毒素呼吸道给药制剂 |
CN102020653A (zh) * | 2009-09-22 | 2011-04-20 | 江苏宏锦天药业有限公司 | 氨基全氢化喹唑啉类化合物及其衍生物制备提高抗癌药药效的新应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0788359B1 (en) | Combination of dextromethorphan with quinidine or quinine sulfate for treating a variety of intractable disorders | |
EP0750909B1 (en) | The use of amino hydrogenated quinazoline compounds and derivatives thereof for abstaining from drug dependence | |
JP5577101B2 (ja) | ブプレノルフィンとナルトレキソンを含む改良医薬組成物 | |
AU2007216320B2 (en) | Combination of alpha-2 receptor agonist (clonidin) and an anti-muscarinic agent (oxybutynin) for the treatment of sialorrhoea | |
US20060229293A1 (en) | Compositions for the treatment of hepatitis C and methods for using compositions for the treatment of hepatitis C | |
JP2018044006A (ja) | 睡眠改善のための低用量ドキセピンの使用法 | |
EP2445489A2 (en) | Compositions for treating drug addiction and improving addiction-related behavior | |
EP2083825A1 (en) | Compositions for the treatment of hepatitis c and methods for using compositions for the treatment of hepatitis c | |
EP0563336B1 (en) | Pharmaceutical composition containing gamma-hydroxybutyric acid or its lactone in the treatment of drug dependence and nutritional disorders | |
CN1054506C (zh) | 药物组合物的用途 | |
CN1081034C (zh) | 一种双胍基氢化嘌呤环类化合物的戒毒药 | |
CN1051706C (zh) | 氨基氢化喹唑啉类化合物及其衍生物戒降药物依赖性的新用途 | |
AU1915192A (en) | Method of treating/preventing substance abuse using 1-alkyl-5(substituted oxy)-2-aminotetralins | |
CN1197568C (zh) | 用于控制广谱疟疾的双氢青蒿素制剂及其制备方法 | |
CN1325305A (zh) | 以低的副作用施用喜树碱化合物治疗癌症的方法 | |
CN1186336C (zh) | 秦皮总香豆素的制备方法及其在制药中的应用 | |
CN1717235A (zh) | 使用巴比土酸衍生物治疗运动障碍的方法 | |
JP2005306882A (ja) | 感情的不安定の治療のための医薬の製造に有用な組成物 | |
CN1209998A (zh) | 一种用于戒毒、止痛的药物制剂及制备方法 | |
CN1175828C (zh) | 一种抗房劳、抗衰老的药物组合物及其制备方法 | |
CN1298374C (zh) | 一种用于戒毒的中药 | |
CN1736380A (zh) | 一种戒毒制剂及其制备方法 | |
CN1524872A (zh) | 茉莉根有效成分及提取方法、用途 | |
CN1215842C (zh) | 阿托品在制备戒毒药物中的用途 | |
Louria | The medical complications of drug abuse |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: ZHONGGUORENMINJIEFANGJUNYAOWUHUAXUEYANJIU INSTITU Free format text: FORMER OWNER: NANNING FENGYE PHARMACEUTICAL CO., LTD. Effective date: 20021122 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20021122 Address after: 102205 1044 box 400, Beijing Patentee after: Qiu Fanglong, Institute of medicinal chemistry, Chinese PLA Address before: 530022, 13-3 Lake Road, Nanning, the Guangxi Zhuang Autonomous Region Patentee before: Nanning Fengye Pharmaceutical Industry Co., Ltd. |
|
C56 | Change in the name or address of the patentee |
Owner name: GUANGZHOU HONGJINTIAN BIOLOGICAL SCIENCE CO., LTD. Free format text: FORMER NAME OR ADDRESS: CHINESE PEOPLE S LIBERATION ARMY INSTITUTE OF MEDICINAL CHEMISTRY; QIU FANGLONG |
|
CP03 | Change of name, title or address |
Address after: 510640 Guangzhou private science and Technology Park 863 industry promotion center two floor Co-patentee after: Qiu Fanglong Patentee after: Guangzhou Acer Jintian Biotechnology Co. Ltd. Address before: 102205 1044 box 400, Beijing Co-patentee before: Qiu Fanglong Patentee before: Institute of medicinal chemistry of PLA |
|
CI01 | Correction of invention patent gazette |
Correction item: Patentee Correct: Guangzhou Acer Jintian Biotechnology Co. Ltd. False: Guangzhou Acer Jintian Biotechnology Co. Ltd.|Qiu Fanglong Number: 36 Volume: 22 |
|
CI03 | Correction of invention patent |
Correction item: Patentee Correct: Guangzhou Acer Jintian Biotechnology Co. Ltd. False: Guangzhou Acer Jintian Biotechnology Co. Ltd.|Qiu Fanglong Number: 36 Page: The title page Volume: 22 |
|
ERR | Gazette correction |
Free format text: CORRECT: PATENTEE; FROM: GUANGZHOU HONGJINTIAN BIOLOGICAL SCIENCE CO., LTD. QIU FANGLONG TO: GUANGZHOU HONGJINTIAN BIOLOGICAL SCIENCE CO., LTD. |
|
ASS | Succession or assignment of patent right |
Owner name: SHENZHEN CITY HONGJINTIAN BIOLOGY SCIENCE CO., LT Free format text: FORMER OWNER: GUANGZHOU HONGJINTIAN BIOLOGICAL SCIENCE CO., LTD. Effective date: 20071221 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20071221 Address after: Unit 8, unit 2, garden 301, Shekou Industrial seven road square, Shenzhen, Nanshan District Patentee after: Shenzhen Hongjintian Biotechnology Technology Co., Ltd. Address before: Guangzhou private science and Technology Park 863 industry promotion center two floor Patentee before: Guangzhou Acer Jintian Biotechnology Co. Ltd. |
|
C17 | Cessation of patent right | ||
CX01 | Expiry of patent term |
Expiration termination date: 20150311 Granted publication date: 20000426 |